

# Shahar Kol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3783930/publications.pdf>

Version: 2024-02-01

114  
papers

3,156  
citations

185998

28  
h-index

174990

52  
g-index

116  
all docs

116  
docs citations

116  
times ranked

1506  
citing authors

#	ARTICLE	IF	CITATIONS
1	GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Human Reproduction Update, 2011, 17, 510-524.	5.2	289
2	The incidence and possible relevance of Y-linked microdeletions in babies born after intracytoplasmic sperm injection and their infertile fathers. Molecular Human Reproduction, 1996, 2, 943-950.	1.3	246
3	GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update, 2006, 12, 333-340.	5.2	208
4	Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication. Human Reproduction, 2000, 15, 1965-1968.	0.4	185
5	Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. Fertility and Sterility, 2014, 101, 1008-1011.	0.5	159
6	Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 2004, 81, 1-5.	0.5	156
7	GnRH agonist triggering: recent developments. Reproductive BioMedicine Online, 2013, 26, 226-230.	1.1	86
8	High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction, 1999, 14, 2242-2244.	0.4	83
9	Endocrinology: Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Human Reproduction, 1996, 11, 1399-1402.	0.4	68
10	The midcycle increase in ovarian glucose uptake is associated with enhanced expression of glucose transporter 3. Possible role for interleukin-1, a putative intermediary in the ovulatory process.. Journal of Clinical Investigation, 1997, 99, 2274-2283.	3.9	62
11	Lower levels of inhibin A and pro-Î±C during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility, 2003, 79, 1123-1128.	0.5	59
12	GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. Human Reproduction, 2011, 26, 2874-2877.	0.4	54
13	A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Human Reproduction, 1999, 14, 2596-2599.	0.4	52
14	Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Human Reproduction, 2012, 27, 753-759.	0.4	48
15	First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462). Human Reproduction, 1998, 13, 294-295.	0.4	46
16	Preoperative diagnosis of fallopian tube carcinoma by transvaginal sonography and CA-125. Gynecologic Oncology, 1990, 37, 129-131.	0.6	43
17	Fertilization and early embryology: Undocumented embryos: do not trash them, FISH them. Human Reproduction, 1996, 11, 2502-2506.	0.4	43
18	Reduced FSH and LH action: implications for medically assisted reproduction. Human Reproduction, 2021, 36, 1469-1480.	0.4	43

#	ARTICLE	IF	CITATIONS
19	A Novel Nonhepatic Hydroxycholesterol 7 $\beta$ -Hydroxylase That Is Markedly Stimulated by Interleukin-1 $\beta$ . <i>Journal of Biological Chemistry</i> , 1995, 270, 18888-18896.	1.6	41
20	Embryo implantation and GnRH antagonists. <i>Human Reproduction</i> , 2000, 15, 1881-1882.	0.4	41
21	LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango?. <i>Reproductive BioMedicine Online</i> , 2010, 21, 590-592.	1.1	40
22	Intraovarian factors regulating ovarian function. <i>Current Opinion in Obstetrics and Gynecology</i> , 1995, 7, 209-213.	0.9	39
23	Infertility in intracytoplasmic-sperm-injection-derived sons. <i>Lancet, The</i> , 1996, 348, 332.	6.3	37
24	"Luteal coasting"™ after GnRH agonist trigger " individualized, HCG-based, progesterone-free luteal support in "high responders"™: a case series. <i>Reproductive BioMedicine Online</i> , 2015, 31, 747-751.	1.1	35
25	Severe OHSS: Yes, there is a strategy to prevent it!. <i>Human Reproduction</i> , 2000, 15, 2266-2267.	0.4	32
26	GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?. <i>Journal of Assisted Reproduction and Genetics</i> , 2008, 25, 63-66.	1.2	31
27	The natural history of multiple pregnancies after assisted reproduction: is spontaneous fetal demise a clinically significant phenomenon?. <i>Fertility and Sterility</i> , 1993, 60, 127-130.	0.5	30
28	Interpretation of nonstress tests by an artificial neural network. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 1372-1379.	0.7	30
29	Rat Ovarian Prostaglandin Endoperoxide Synthase-1 and -2: Periovarian Expression of Granulosa Cell-Based Interleukin-1-Dependent Enzymes. <i>Endocrinology</i> , 1998, 139, 2501-2508.	1.4	29
30	Use of Gonadotropin- Releasing Hormone Agonist to Cause Ovulation and Prevent the Ovarian Hyperstimulation Syndrome. <i>Clinical Obstetrics and Gynecology</i> , 1993, 36, 701-710.	0.6	28
31	Glucocorticoids suppress basal (but not interleukin-1-supported) ovarian phospholipase A2 activity. Supported in part by Research Grant HD-30288 from the NICHD, NIH (EYA), Lalor Foundation Fellowship, an International Fellowship Award from the Israeli Medical Foundation, a Fullbright Fellowship, and a Harlea Charitable Trust Award (IBS). <i>Molecular and Cellular Endocrinology</i> , 1998, 137, 117-125.	1.6	27
32	Ovarian hyperstimulation syndrome after using onadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. <i>Human Reproduction</i> , 1996, 11, 1143-1144.	0.4	26
33	Early transvaginal embryo aspiration: a safer method for selective reduction in high order multiple gestations. <i>Human Reproduction</i> , 1999, 14, 1875-1878.	0.4	26
34	The rat intraovarian interleukin (IL)-1 system: cellular localization, cyclic variation and hormonal regulation of IL-1 $\beta$ and of the type I and type II IL-1 receptors. <i>Molecular and Cellular Endocrinology</i> , 1999, 149, 115-128.	1.6	26
35	GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism. <i>Gynecological Endocrinology</i> , 2017, 33, 741-745.	0.7	25
36	The Rat Ovarian Phospholipase A2 System: Gene Expression, Cellular Localization, Activity Characterization, and Interleukin-1 Dependence. <i>Endocrinology</i> , 1997, 138, 322-331.	1.4	24

#	ARTICLE	IF	CITATIONS
37	The presence of a sponsoring embryo in a batch of poor quality thawed embryos significantly increases pregnancy and implantation rate. <i>Fertility and Sterility</i> , 1997, 67, 711-716.	0.5	23
38	“Model” versus “everyday” patients: can randomized controlled trial data really be applied to the clinic?. <i>Reproductive BioMedicine Online</i> , 2017, 34, 274-279.	1.1	23
39	Detection and in vivo hormonal regulation of rat ovarian type I and type II interleukin-1 receptor mRNAs: Increased expression during the periovulatory period. <i>Journal of the Society for Gynecologic Investigation</i> , 1996, 3, 131-139.	1.9	23
40	Helium and Oxygen Treatment of Severe Air-Diving-Induced Neurologic Decompression Sickness. <i>Archives of Neurology</i> , 1997, 54, 305-311.	4.9	22
41	Interleukin (IL)-1 $\beta$ Increases Glucose Uptake and Induces Glycolysis in Aerobically Cultured Rat Ovarian Cells: Evidence That IL-1 $\beta$ May Mediate the Gonadotropin-Induced Midcycle Metabolic Shift*. <i>Endocrinology</i> , 1997, 138, 2680-2688.	1.4	21
42	Ovarian Interleukin-1 Receptor Antagonist in Rats: Gene Expression, Cellular Localization, Cyclic Variation, and Hormonal Regulation of a Potential Determinant of Interleukin-1 Action1. <i>Biology of Reproduction</i> , 1999, 61, 274-282.	1.2	20
43	Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research. <i>Reproductive BioMedicine Online</i> , 2005, 10, 575-577.	1.1	20
44	Change, change, change: hormonal actions depend on changes in blood levels. <i>Human Reproduction</i> , 2008, 23, 1004-1006.	0.4	20
45	The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors. <i>Reproductive BioMedicine Online</i> , 2015, 30, 563-565.	1.1	20
46	Gonadotropin-Releasing Hormone Agonist Trigger: The Way to Eliminate Ovarian Hyperstimulation Syndrome—A 20-Year Experience. <i>Seminars in Reproductive Medicine</i> , 2010, 28, 500-505.	0.5	18
47	Ovarian interleukin-1-induced gene expression: privileged genes threshold theory. <i>Medical Hypotheses</i> , 2002, 58, 6-8.	0.8	17
48	To add or not to add LH: consideration of LH concentration changes in individual patients. <i>Reproductive BioMedicine Online</i> , 2005, 11, 664-666.	1.1	17
49	Human embryonal extracts modulate placental function in the first trimester: Effects of visceral tissues upon chorionic gonadotropin and progesterone secretion. <i>Placenta</i> , 1989, 10, 331-344.	0.7	16
50	Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!. <i>Human Reproduction</i> , 2003, 18, 1557-1558.	0.4	16
51	Simplified riboprobe purification using translucent straws as gel tubes. <i>Genetic Analysis, Techniques and Applications</i> , 1996, 12, 129-132.	1.5	14
52	Ovarian Expression, Cellular Localization, and Hormonal Regulation of Rat Secretory Phospholipase A2: Increased Expression by Interleukin-1 and by Gonadotropins1. <i>Biology of Reproduction</i> , 1997, 57, 217-225.	1.2	14
53	Non-steroidal anti-inflammatory drugs (NSAIDs) block the late, prostanoid-dependent/ceramide-independent component of ovarian IL-1 action: implications for the ovulatory process. <i>Molecular and Cellular Endocrinology</i> , 1999, 157, 21-30.	1.6	14
54	Treatment Strategies for the Infertile Polycystic Ovary Syndrome Patient. <i>Women's Health</i> , 2015, 11, 901-912.	0.7	14

#	ARTICLE	IF	CITATIONS
55	GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?. <i>Reproductive BioMedicine Online</i> , 2018, 36, 75-77.	1.1	14
56	Hyperbaric oxygenation for necrotizing fasciitis. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 1336.	0.7	13
57	Interleukin-1 $\beta$ Stimulates Ovarian Phospholipase A2(PLA2) Expression and Activity: Up-Regulation of Both Secretory and Cytosolic PLA21. <i>Endocrinology</i> , 1997, 138, 314-321.	1.4	13
58	The low responder, hypogonadotropic hypogonadism female patient in IVF: do not give up!. <i>Fertility and Sterility</i> , 2000, 74, 401-402.	0.5	13
59	The Rat Ovarian Phospholipase A2 System: Gene Expression, Cellular Localization, Activity Characterization, and Interleukin-1 Dependence. , 0, .		13
60	Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation. <i>Reproductive BioMedicine Online</i> , 2009, 19, 59-60.	1.1	12
61	The gonadotropin-releasing hormone antagonist protocol – the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 643-647.	1.3	12
62	The use of GnRH analogs for induction of the preovulatory gonadotropin surge in assisted reproduction and prevention of the ovarian hyperstimulation syndrome. <i>Gynecological Endocrinology</i> , 1995, 9, 13-17.	0.7	11
63	Ovarian Origin of Plasma and Peritoneal Fluid Prorenin in Early Pregnancy and in Patients with Ovarian Hyperstimulation Syndrome*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 461-464.	1.8	11
64	Should Cochrane reviews be performed during the development of new concepts?. <i>Human Reproduction</i> , 2012, 27, 6-8.	0.4	11
65	Individualized Treatment from Theory to Practice: The Private Case of Adding LH during GnRH Antagonist-based Stimulation Protocol. <i>Clinical Medicine Insights Reproductive Health</i> , 2014, 8, CMRH.S17788.	3.9	11
66	Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression and activity. <i>Molecular Human Reproduction</i> , 1997, 3, 1095-1099.	1.3	9
67	In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2007-2014. <i>Israel Journal of Health Policy Research</i> , 2016, 5, 14.	1.4	9
68	LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 307-311.	0.7	9
69	Luteal phase support post IVF: individualized early stop. <i>Reproductive BioMedicine Online</i> , 2015, 31, 633-637.	1.1	8
70	GnRH agonist trigger does not always cause luteolysis: a case report. <i>Reproductive BioMedicine Online</i> , 2016, 32, 132-134.	1.1	8
71	Distinct and independent dielectrophoretic behavior of the head and tail of sperm and its potential for the safe sorting and isolation of rare spermatozoa. <i>Electrophoresis</i> , 2019, 40, 1606-1614.	1.3	8
72	Rat Ovarian Interleukin-1 $\beta$ : Interleukin-1-Dependent In Vitro Expression. <i>Endocrine</i> , 1999, 11, 269-276.	2.2	7

#	ARTICLE	IF	CITATIONS
73	A case of severe early-onset OHSS after GnRH-agonist triggering. <i>Fertility and Sterility</i> , 2011, 96, e151.	0.5	7
74	Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger – a proof of concept study. <i>Gynecological Endocrinology</i> , 2018, 34, 132-135.	0.7	7
75	A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 1-5.	0.7	7
76	Rat Ovarian Prostaglandin Endoperoxide Synthase-1 and -2: Periovulatory Expression of Granulosa Cell-Based Interleukin-1-Dependent Enzymes. , 0, .		7
77	Ovarian stimulation in in vitro fertilization with or without the –gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome. <i>Fertility and Sterility</i> , 2000, 74, 166-168.	0.5	6
78	GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte retrieval for luteal phase support. <i>Reproductive BioMedicine Online</i> , 2020, 41, 854-858.	1.1	6
79	Suboptimal response to GnRH agonist trigger: causes and practical management. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 213-217.	0.9	6
80	Interleukin (IL)-1 <sup>β</sup> Increases Glucose Uptake and Induces Glycolysis in Aerobically Cultured Rat Ovarian Cells: Evidence That IL-1 <sup>β</sup> May Mediate the Gonadotropin-Induced Midcycle Metabolic Shift. , 0, .		6
81	Anovulatory Patients Demonstrate a Sharp Decline in LH Levels upon GnRH Antagonist Administration during IVF Cycles. <i>Rambam Maimonides Medical Journal</i> , 2017, 8, e0021.	0.4	6
82	Reply: Investigating actions of changing hormone levels. <i>Human Reproduction</i> , 2008, 23, 2611-2611.	0.4	5
83	Time, time, time: see what governs the luteal phase endocrinology. <i>Gynecological Endocrinology</i> , 2021, 37, 775-777.	0.7	5
84	The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients. <i>Reproductive BioMedicine Online</i> , 2021, 42, 1108-1118.	1.1	5
85	Transforming growth factor-beta1 is a potent inhibitor of interleukin-1beta action in whole ovarian dispersates. <i>Journal of Endocrinology</i> , 1999, 160, 415-423.	1.2	4
86	–GnRH agonist trigger: looking for the coin under the lamp post?–™. <i>Human Reproduction</i> , 2006, 21, 1328-1328.	0.4	4
87	The vanishing follicle in women aged over forty: Premature, mechanical, LH-independent luteinization may reflect oocyte–follicle low quality?. <i>Medical Hypotheses</i> , 2008, 70, 1227-1228.	0.8	4
88	The use of portable CO <sub>2</sub> incubator for cross-border shipping of embryos in an international egg donation program. <i>Gynecological Endocrinology</i> , 2014, 30, 755-757.	0.7	4
89	The Importance of Mid-Follicular Phase Luteinizing Hormone Rise in GnRH Antagonist-Based Ovarian Stimulation for IVF. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 184-188.	0.7	4
90	The Role of Growth Factors in Ovarian Function and Development. , 0, , .	0.0	4

#	ARTICLE	IF	CITATIONS
91	Assisted Implantation: Direct Intraendometrial Embryo Transfer. <i>Gynecologic and Obstetric Investigation</i> , 1997, 43, 73-75.	0.7	3
92	Luteal support post GnRH agonist trigger: do not stop too soon. <i>Human Reproduction</i> , 2005, 20, 3257-3257.	0.4	3
93	Ultrasound-guided embryo transfer—a special role in patients with certain uterine defects. <i>Fertility and Sterility</i> , 2008, 89, 260.	0.5	3
94	Ultra-Orthodox Jews and infertility diagnosis and treatment. <i>Andrology</i> , 2018, 6, 662-664.	1.9	3
95	Thyroid Function in Early Normal Pregnancy: Transient Suppression of Thyroid-Stimulating Hormone and Stimulation of Triiodothyronine. <i>Gynecologic and Obstetric Investigation</i> , 1996, 42, 227-229.	0.7	2
96	Expression and hormonal regulation of rat ovarian interleukin-1 $\beta$ converting enzyme, a putative apoptotic marker: endocrine- and paracrine-dependence. <i>Journal of Reproductive Immunology</i> , 1999, 45, 67-79.	0.8	2
97	Vascular endothelial growth factor—a mediator of PHSS?. <i>Fertility and Sterility</i> , 2003, 79, 1466.	0.5	2
98	Society's contribution to assisted reproductive technology abuse. <i>Human Reproduction</i> , 2005, 20, 2362-2362.	0.4	2
99	Agonist trigger in the context of OHSS prevention: primum non nocere. <i>Human Reproduction Update</i> , 2006, 12, 327-328.	5.2	2
100	Reply: GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data. <i>Human Reproduction Update</i> , 2012, 18, 229-230.	5.2	2
101	False positive blood hCG test following Corifollitropin alfa injection. <i>Human Reproduction</i> , 2018, 33, 177-177.	0.4	2
102	IVF and the exogenous progesterone-free luteal phase. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 188-195.	0.9	2
103	Reproductive endocrinology electronic mail list. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1994, 73, 365-365.	1.3	1
104	Adjuvant Hyperbaric Oxygenation Therapy in Hand Edema and Ischemia. <i>Techniques in Hand and Upper Extremity Surgery</i> , 1998, 2, 274-277.	0.3	1
105	Evidence-based medicine or just a theory?. <i>Fertility and Sterility</i> , 2009, 92, e9.	0.5	1
106	GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care Campus. <i>Rambam Maimonides Medical Journal</i> , 2017, 8, e0023.	0.4	1
107	Intravenous glucose tolerance test in gestational diabetes and pregnancy: a manual™ versus computerized assessment. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1988, 27, 307-311.	0.5	0
108	Reply of the author. <i>Fertility and Sterility</i> , 1997, 68, 1152-1153.	0.5	0

#	ARTICLE	IF	CITATIONS
109	Avoiding neurological injury. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1997, 11, 684.	0.6	0
110	The Incidence and Possible Relevance of Y-Linked Microdeletions in Babies Born After Intracytoplasmic Sperm Injection and Their Infertile Fathers. <i>Journal of Urology</i> , 1998, 159, 609-610.	0.2	0
111	9: Progesterone promotes the expansion of proangiogenic immature myeloid cells and prevents their differentiation into inflammatory cells. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, S8.	0.7	0
112	The Role of GnRH Agonist Triggering in GnRH Antagonist-Based Ovarian Stimulation Protocols. , 2019, , 363-377.		0
113	Triggering Ovulation with GnRH Analogs. , 2000, , 308-316.		0
114	Reproductive endocrinology electronic mail list. <i>Neuro-Ophthalmology</i> , 1992, 12, 365-365.	0.4	0